← Back to all trials
Active Not Recruiting
NCT07333261
Study of BMS-986453 in Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma
Sex: All
Ages: 19 Years – N/A
Healthy volunteers: No
Phase: PHASE1
Enrollment: 25
Sponsor: Susan Bal
Location: University of Alabama at Birmingham Birmingham Alabama
Summary
This is a phase 1b study evaluating if BMS-986453 is safe and effective in treating people who have newly diagnosed multiple myeloma after completing initial therapy (induction) when a stem cell transplant is not intended.
Eligibility Criteria
Inclusion Criteria:
1. Age \> 18 years with no upper age limit
2. NDMM with indication for initiation of therapy diagnosed within last 12 months. Pretreatment parameters necessary for disease characterization and response assessment must be available.
3. Not eligible for ASCT by institutional criteria or deferring ASCT due to personal preference.
4. ECOG performance status 0-1
5. Adequate organ function
Exclusion Criteria:
1. Known active or history of central nervous system (CNS) involvement of MM.
2. Plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS or clinically significant amiloidosis.
3. Prior history of other malignancies
4. Uncontrolled infection
Other protocol-defined Inclusion/Exclusion criteria apply.
Source: ClinicalTrials.gov (NCT07333261). StuddyBuddy aggregates publicly available trial information.
